The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Bind Therapeutics, Inc. Common Stock 05548N107 4,622 2,018,253 SH   SOLE   2,018,253 0 0
Fate Therapeutics, Inc. Common Stock 31189P102 8,335 2,473,186 SH   SOLE   2,473,186 0 0
Genocea Biosciences, Inc. Common Stock 372427104 10,375 1,968,606 SH   SOLE   1,968,606 0 0
Trevena, Inc. Common Stock 89532E109 28,027 2,669,280 SH   SOLE   2,669,280 0 0
Cerulean Pharma Inc Common Stock 15708Q105 9,205 3,287,529 SH   SOLE   3,287,529 0 0
Ocular Therapeutix, Inc. Common Stock 67576A100 11,525 1,230,009 SH   SOLE   1,230,009 0 0
T2 Biosystems, Inc. Common Stock 89853L104 22,082 2,018,450 SH   SOLE   2,018,450 0 0
Atyr Pharma Inc. Common Stock 002120103 17,969 1,827,992 SH   SOLE   1,827,992 0 0
Pulmatrix Inc. Common Stock 74584P103 15,154 3,607,996 SH   SOLE   3,607,996 0 0